Columvi: Dosage Form, Projected Sales, NCE-1 Date | Glofitamab-Gxbm

Columvi

Columvi is an antibody-based therapy for adults with relapsed or refractory diffuse large B-cell lymphoma. It activates the immune system to target and destroy cancer cells when other treatments have failed.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Glofitamab-Gxbm
Innovator :

ROCHE
Approval Date :

15-Jun-23
Data Exclusivity Expiry :

15-Jun-27
Market Exclusivity Expiry :

15-Jun-35
Dosage Form :

IV Injection
Strength :

2.5mg/2.5ml and 10mg/10ml
Therapeutic Category :

Anticancer
Revenue ($M) :

195

Year-wise Projected Sales ($M) :

2025 :

387
2026 :

624
2027 :

890
2028 :

1,163
2029 :

1,394
2030 :

1,618
2031 :

1,840

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Columvi

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?